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Abstract 
Hexavalent chromium or Cr(VI) is a known carcinogen in human beings, though the 
exact mechanism of carcinogenicity is still unknown. The same chemical compound is also 
found at varying levels in the water sources of more than 200 million Americans. While the 
government currently regulates total chromium levels, they have yet to determine a 
permissible exposure limit for Cr(VI). There is currently no method of preventative treatment 
for the chemical. The focus of this study was to determine the mechanism of carcinogenicity of 
Cr(VI) as well as confirm the viability of antioxidants as a preventative treatment. Because of 
Cr(VI)’s strong oxidative power, we hypothesized that the chemical causes DNA mutation and 
cell death via oxidation and that antioxidants could prevent this from occurring. To test this 
theory, we exposed human cell culture to Cr(VI) and samples of Cr(VI) cotreated with either 
vitamin C or epigallocatechin gallate (EGCG). An Ames test was also performed to determine 
the mutagenicity of Cr(VI) as well as cotreatments of the toxicants with antioxidant.  
It was found that Cr(VI) is significantly toxic to cell culture at concentrations of 200 ppb 
(parts per billion) or more. Both vitamin C and EGCG blocked this effect at 10 ppm (parts per 
million) and 15 ppm, respectively. Neither antioxidant was observed to be cytotoxic when 
treated alone. Cr (VI) was also found to be significantly mutagenic at 20 ppb and up. This 
mutagenicity was significantly reduced by cotreatment with 20 ppm vitamin C at 200 and 2000 
ppb Cr. Vitamin C was not found to be mutagenic when treated individually. With this 
combined data, we can conclude that hexavalent chromium is both cytotoxic and mutagenic via 
an oxidative mechanism and these effects can be abrogated by antioxidants. Though continued 
study is merited, this information further validates the protective potential of antioxidants.
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Introduction 
Hexavalent Chromium 
The toxicological effects of hexavalent chromium (Cr(VI)) compounds have been widely 
studied over the years. Specifically, data have been collected to assess its carcinogenic effects 
on humans through case study (Yu, 2013), its toxicological effects on rats (Geetha et al., 2003), 
and on a number of cellular cultures as well (Majone et al., 2002). While there exist 3 different 
oxidative states for chromium, the hexavalent form has been found to be much more toxic than 
the quadrivalent form or the trivalent form, which in fact is an essential element for humans 
(Sun et al., 2015). Unfortunately, the toxicant can be found in hexavalent form in the tap water 
of nearly two thirds of the United States’ drinking supply (Andrews & Walker, 2016). While the 
environmental protection agency (EPA) monitors total chromium levels in our water, 
hexavalent levels are not monitored, and the toxicant is ingested daily. The EPA’s current 
maximum contaminant level (MCL) for total chromium is 100 ppb, however Cr(VI) at 100 ppb 
could have detrimental effects on a population. In humans, hexavalent chromium toxicity 
through ingestion has been known to cause cardiovascular, gastrointestinal, hematological, 
hepatic, renal, and neurological damage, and in severe cases, causes cancer or death (Yu, 2013). 
Furthermore, roughly ten percent of inorganic Cr(VI) is absorbed through the intestinal tract 
(Yu, 2013). Excretion of absorbed chromium occurs primarily via urine. In humans, the kidney 
excretes about 60% of an absorbed Cr(VI) dose in the form of Cr(III) within 8 hours of ingestion. 
Approximately 10% of an absorbed dose is eliminated by biliary excretion, with smaller 
amounts excreted in hair, nails, milk, and sweat (Kiilunen & Kivisto, 1983). Clearance from 
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plasma is generally rapid (within hours), whereas elimination from tissues is slower, with a half-
life of several days (ATSDR, 2012). 
Chromium is a naturally occurring element and often found in both the hexavalent and 
trivalent states in natural watersheds (Loyaux-Lawniczak et al, 2001). However, chromium 
compounds are often used for chromium plating and other industrial uses as well (Kamerud et 
al., 2013). Disposal of chromium containing commercial products and coal ash from electric 
utilities and other industries are major sources of chromium releases into the soil (Barceloux 
1999). Solid waste and slag produced during chromate manufacturing processes can be 
potential sources of chromium exposure as well (Barceloux 1999). Improper disposal and 
maintenance of the chemical at these facilities can cause environmental contamination and 
drinking water pollution (Cone, 2009). A recent study done on Illinois water showed that 
hexavalent chromium concentrations were actually higher in treated water than those in 
untreated water. Cr(VI) levels on surface water were found to be 0.3 ppb, and levels in bedrock 
aquifers at 1.1 ppb, whereas those in treated water supplies were 2.4 ppb, indicating that water 
treatment practices may ironically play a role in increasing concentrations (Mills & Cobb, 2015).  
Mechanism of Toxicity 
The mechanism of toxicity of Cr(VI) has been found to be induction of oxidative stress 
which further leads to cell toxicity and cell death (Bagchi et al., 2002; Chiu et al., 2010). 
Oxidative stress results when reactive oxygen species (ROS), either produced endogenously as a 
consequence of normal cellular functions or derived from external sources, cause damage that 
exceeds the cell’s ability to resist oxidation (Martindale & Holbrook, 2002). When ROS originate 
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from exogenous sources, they are either taken up directly by cells from the extracellular matrix 
or produced as a consequence of the cell's exposure to some environmental antagonist 
(Martindale & Holbrook, 2002). Transient fluctuations in ROS serve important regulatory 
functions such as in aerobic respiration, but when present in high levels, ROS can cause severe 
damage to DNA, protein, and lipids (Martindale & Holbrook, 2002). A number of cellular 
defense mechanisms have evolved to combat the accumulation of ROS. These include various 
non‐enzymatic molecules such as glutathione, and vitamins A, C, and E, as well as enzymatic 
scavengers of ROS like superoxide dismutase and catalase (Martindale & Holbrook, 2002). 
Unfortunately, these systems of defense are not always adequate to counteract the production 
of ROS, resulting in what is termed a state of oxidative stress. Because of its 6+ oxidation state, 
Cr(VI) is a very powerful oxidizer.  
Ames Assay 
Previous study shows that not only are hexavalent chromium compounds carcinogenic, 
but they are also directly mutagenic towards deoxyribonucleic acid (DNA) (Petrilli & Deflora, 
1976). In this procedure, a genetically engineered strain of Salmonella typhimurium was 
exposed to differing solutions to test mutagenic potential. When exposed to a mutagen, this 
specific strain of bacteria will revert from a state of auxotrophy (inability to produce the 
essential amino acid histidine), to a state of prototrophy (ability to produce histidine). This 
genetic reversion allows the bacteria to survive and replicate whereas a lack of mutation will 
result in death. Bacterial survival, observed by colorimetric determination of its growth media, 
is therefore a direct indicator of DNA mutagenesis. This same study showed that the mutagenic 
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effects were caused directly by the Cr(VI) and not due to a metabolic byproduct within the 
bacteria (Petrilli & Deflora, 1976).  
Reduction Potential 
One study showed that the use of certain microorganisms as a biological filter could be 
used to lower chromium levels (Thatoi et al., 2014), and several others have shown that 
antioxidants have chromium reduction potential against chromium as well (Chrysochoou & 
Reeves, 2016; Geetha et al., 2003). Antioxidants lower the oxidation state of chromium from 6+ 
to the lower, less harmful state of 3+. One study showed that epigallocatechin gallate (EGCG) 
directly reduces Cr(VI) in solution (Chrysochoou & Reeves, 2013), while another showed that 
Vitamin C also reduces Cr(VI) in solution and in the past has been used as a topical treatment 
against Cr(VI) skin exposure (Yu, 2013). A third study tested the effect of antioxidants extracted 
from the plant Hippophae rhamnoides on albino rats when co-fed with hexavalent chromium. 
Results suggested that rats which had been fed antioxidants along with the chromium 
compounds exhibited declines in tumor growth both in size and frequency than those which 
had been fed chromium compounds without any antioxidant present (Geetha et al., 2003). 
While this study demonstrates that a plant extract with antioxidant properties prevents Cr(VI)-
induced toxicity at the organismal level, little is known about the effects of specific antioxidants 
on cellular culture. To date, there have been no studies of Cr(VI) and antioxidant cotreatment 
upon human cell culture, and while antioxidants are known to reduce Cr(VI), there is still 
uncertainty in regard to which antioxidants are most effective. Additionally, the extent to which 
antioxidants are protective has yet to be elucidated; whether they protect against cytotoxicity 
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upon the cell membrane and within the cytoplasm, or if they protect against mutagenesis 
within the nucleus as well. 
 
Methods 
Cellular culture, compounds, and storage 
Human intestinal epithelial (HInEpi) cells were obtained from the American Type Culture 
Collection (ATCC) and were sustained on the cell line’s respective ATCC media. Human 
embryonic kidney (HEK) cells were obtained from a secondary passage in nitrogen storage in 
house at Reed Hall of Science, though the original passage was obtained from Loyola University. 
These cells were sustained on Dulbecco’s Modified Eagle Medium with 10% Fetal Bovine 
Serum, 1% Penicillin-Streptomycin, and 1% L-Glutamine, all of which were sourced from Sigma 
Aldrich. Cells were incubated at 37°C and 5% CO2 and passaged once confluent using trypsin-
EDTA. Both L-Ascorbic Acid and Epigallocatechin Gallate were obtained from Sigma Aldrich. The 
Cr(VI) (hexavalent chromium) compound used for experimentation was potassium chromate, 
also obtained from Sigma Aldrich. 
Determination of treatment concentration 
Experimental Cr(VI) concentrations were tested in magnitudes of 10 ranging from 2 ppb 
(parts per billion) to 20,000 ppb to simulate environmental conditions as well as coincide with 
previous literature. These concentrations were used for both cell proliferation and Ames 
procedures. Antioxidant concentrations were determined through experimentation, starting at 
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a 1:1 ratio of antioxidant to Cr(VI) and adjusted accordingly based on response until effects 
were seen.  
Solution Preparation 
Stock solutions of Cr(VI), EGCG and ascorbic acid were prepared by dissolving solute in 
double-distilled water at a concentration of 2000 ppm and then filter sterilizing under a filtrated 
hood. Once treatment concentrations had been determined as described above, smaller 
aliquots of stock solution were mixed with the appropriate cell media to bring the final mixture 
to the desired experimental concentration. Experimental solution containing both Cr(VI) and an 
antioxidant for cotreatment were prepared by bringing both a Cr(VI) solution and an 
antioxidant solution to twice their desired final concentration in media and then adding the two 
solutions together to dilute the sample down to its experimental concentration. Stock solutions 
were stored at 4°C and were remade several times throughout experimentation to avoid 
expiration. Experimental solutions were made within 24 hours of use. 
Cellular proliferation assay 
All cell culture work was done under a sterile hood. Both the HInEpi and HEK cells were 
passaged in T-75 flasks in their untreated, respective media until confluency was reached. 
These cells were then passaged onto a 24-well plate and again cultured within their untreated 
media until wells reached confluency. Treatment groups were then run in quadruplicate, 
allowing for 6 sample groups per plate. Cells were exposed to solution for 72 hours. To depict 
qualitative results, photos were taken of wells at points of interest along the way using a Nikon 
TXI. 
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After the 72-hour incubation period, media was aspirated and then cells were 
trypsinized and suspended in solution. 10 μl of solution was taken from each well and then 
mixed with equal parts Trypan blue. After at least a minute to allow for cell staining to occur, 10 
μl of cell suspension/trypan stain solution was drawn off and dispensed over a hemocytometer 
for counting of viable cells to determine number of cells per treatment group.  
Ames assay 
Ames test kits were purchased from Environmental Bio-detection Products Inc. (EBPI) 
and the assay was carried out according to manufacture instructions. The lyophilized bacterial 
culture was suspended in a liquid media (Reagent G) 12-16 hours prior to experimentation. 
Once suspended, the bacteria were placed in a shaking incubator at 37°C to replicate and grow 
overnight. The following day, experimental samples were prepared by diluting the Cr(VI) stock 
solution in sterile water to desired concentrations. Turbidity within the bacterial culture verified 
growth and the OD600 of the solution was measured by spectrophotometry. This OD (optical 
density) value was then used to bring the bacterial suspension to a desired concentration 
through a series of calculations. 3 samples of each treatment group were placed in a 24-well 
plate for the bacterial exposure period. Positive, negative and sterility controls were also done 
on the exposure plate. Added into each well was the treatment solution, exposure media, and 
the bacterial suspension, and the plate was incubated at 37°C for 100 minutes. During 
incubation period, a reversion media was prepared for the 96-well plates. After the bacteria 
had been incubated for 100 minutes, the plate was removed and solution from each well was 
pipetted into a tube containing the premade reversion media. Using loading boats and a 
multichannel pipette, each sample was pipetted into 48 wells of a 96-well plate. The 96-well 
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plates were then placed in an incubator at 37°C for 3 days to allow for revertant bacteria to 
grow. After the 3 day incubation period, plates were scored by colorimetric determination with 
yellow and partial-yellow wells indicating genetic reversion. 
Statistical analysis 
The statistical analysis for both the cell proliferation data and the Ames assay data were 
done by a two-tailed t-test data with p-values < 0.05 determined to be statistically significant. 
 
Results 
 
Cr(VI) was shown to exhibit a negative 
dose response when exposed to HEK cells. 
Figure 1 shows that the negative control 
group of untreated media resulted in 570,000 
cells per well after a three-day exposure 
period. 200 ppb Cr(VI) solution resulted in 
383,750 cells per well, and 500 ppb Cr(VI) 
resulted in 66,250 cells per well while        
1000 ppb completely eradicated all cells in 
the treatment group. These data made way for the addition of antioxidants to Cr(VI) solution.  
Figure 2 shows that 500 ppb chromium was kept constant while varying concentrations 
of vitamin C were added as cotreatment. 50 ppm vitamin C was also run independently as a 
Figure 1: Dose response to Cr(VI) Human 
embryonic kidney cells were exposed to 
different doses of Cr(VI) ranging from 200      
ppb - 1000 ppb. A negative dose response to 
Cr(VI) was observed. 
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control group and yielded similar cell 
counts as the negative control. 500 ppb 
Cr(VI) cotreated with 5 ppm VC 
increased cells per well from 500 ppb 
Cr(VI) alone. These counts were 
186,250 and 66,250 respectively. Wells 
cotreated with Cr(VI) and 10 ppm VC 
yielded 467,500 cells per well and 
those cotreated with VC concentrations 
at 25 ppm yielded 590,000 cells per well. There is no statistically significant difference between 
the negative control and 50 ppm VC. There is also no significant difference between 500 ppb 
Cr(VI) cotreated with 25 ppm VC and the negative control.  
These results were replicated qualitatively upon a second cell line. Human Intestinal 
epithelial cells were exposed to the same treatment groups as shown in Figures 1 and 2. Due to 
Figure 2: Dose response to Cr(VI) and vitamin C 
cotreatment. Human embryonic kidney cells were 
exposed to cotreated samples of 500 ppb Cr(VI) and 
differing concentrations of vitamin C. Likelihood of 
survival increased with the addition of vitamin C. Cr(VI) 
was completely mitigated by 25ppm vitamin C.  
 
Figure 3: Human intestinal epithelial cells exposed to Cr(VI) and vitamin C. Cells were exposed to 
untreated cell media (panel A), as well as 500 ppb Cr(VI) (panel B) and 500 ppb Cr(VI) cotreated 
with 25 ppm vitamin C (panel C). Cotreatment mitigated nearly all observed effects of Cr(VI). This 
result was replicated on human embryonic kidney cells. These images were taken 3 days after 
exposure. 
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difficulties in the cell counting procedure for this particular line of cells, representative pictures 
of treatment groups were taken to serve as alternative results to quantification. Panel B in 
Figure 3 depicts 500 ppb Cr(VI) exposure whereas panel C shows cotreatment with 25 ppm VC. 
Panels A and C look relatively similar, while panel B shows undeniable cytotoxicity and cell 
necrosis. 
HEK cells were also 
exposed to Cr(VI) solutions 
cotreated with EGCG. Figure 
4 depicts exposure to 500 
ppb Cr(VI) and solutions 
cotreated with EGCG ranging 
from 5 ppm to 50 ppm. In 
this trial, 500 ppb Cr(VI) resulted 
in 94,500 cells per well. 500 ppb 
Cr(VI) cotreated with 5 ppm EGCG also resulted in 94,500 cells per well. Upon further addition 
of EGCG, cell survival increased up to the final treatment group of 500 ppb Cr(VI) with 50 ppm 
EGCG which yielded a cell count of 460,250. Negative control in this exposure trial yielded 
796,250 cells per well and 50 ppm EGCG, 759,500. 
Figure 5 depicts the results of the Ames assay, which was performed identically five 
separate times throughout the course of experimentation. As Cr(VI) concentrations increased 
from 2 ppb to 2000 ppb, percent mutagenicity increased. Treatment groups of 20, 200 and 
2000 ppb were significantly more mutagenic than the negative control. 200 ppb and 2000 ppb 
Figure 4: Dose response to Cr(VI) and EGCG cotreatment. 
Human embryonic kidney cells were exposed to solutions of 
500 ppb Cr(VI) cotreated with varying concentrations of EGCG. 
As EGCG concentrations increased, cell survival also increased. 
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Cr(VI) cotreated with 20 ppm vitamin C were significantly less mutagenic than their Cr(VI)-only 
treated counterparts. 20 ppm vitamin C was not found to be mutagenic itself.  
 
Discussion 
These data suggest that Cr(VI) is cytotoxic via an oxidative mechanism. After exposing 
human embryonic kidney cells to a range of Cr(VI) concentrations, we can see that the 
contaminant has a direct influence on cell death, with higher concentrations of chromium 
leading to a lower likelihood of cell survival (Figure 1). These same results were also observed 
qualitatively on Human Intestinal Epithelial cells, with higher concentrations of Cr(VI) leading to 
greater cell death. Furthermore, these effects were mitigated by the addition of antioxidants 
Figure 5: Bacteria exposed to Cr(VI) and vitamin C to test mutagenic potential. Bacterial cultures exposed 
to solution containing higher levels of Cr(VI) were more likely to mutate DNA. Those exposed to high levels 
of Cr(VI) as well as vitamin C were less likely to mutate. * denotes p-value < 0.05 when compared to 
negative control, ** denotes p-value < 0.005 when compared to negative control, # denotes p-value < 0.05 
compared to that concentration of Cr(VI) alone. 
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within cell solution. Both ascorbic acid and epigallocatechin gallate prevented cytotoxicity and 
necrosis (Figures 2 and 4). This evidence suggests that Cr(VI) is indeed cytotoxic via an oxidative 
mechanism as the presence of an antioxidant reduced cytotoxicity. 
Ascorbic acid was found to be a much more potent protective chemical than 
epigallocatechin gallate (Figures 2 and 4). This could be due to the vast difference in the size of 
the two molecules as ascorbic acid is much smaller than its counterpart. It’s unclear where the 
reduction of Cr(VI) into Cr(III) is occurring, whether inside the cell in the cytoplasm or outside 
the cell within the culture media, though it is probable that the majority is occurring in the 
media before the toxicant enters the cell. 
Data from the Ames assay continues to suggest that Cr(VI) is mutagenic by way of 
oxidation. As bacterial strains were exposed to increasing concentrations of the toxicant, 
percent mutation increased as well. When exposed to solution cotreated with antioxidant 
however, percent mutation was essentially nullified as levels were brought back down to those 
observed within the negative control group, regardless of the concentration of Cr(VI). That is, 
any group treated with vitamin C exhibited no significant change from the negative control, 
even at the highest treated concentration of Cr(VI) (2000 ppb). 
Furthermore, neither antioxidant tested was found to be cytotoxic or mutagenic in-and-
of-itself. This serves as crucial information as the ultimate purpose that they may serve as is a 
preventative protectant, pre-treated within a drinking water supply. We cannot pre-treat the 
water with a level of protectant so high that it itself becomes a harmful contaminant. This 
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concern is needless as both vitamin C and EGCG showed great protective potential at levels at 
which they themselves were harmless. 
It appears that Cr(VI) is more mutagenic towards bacterial DNA at lower concentrations 
(20 ppb) than it is cytotoxic towards mammalian cells (200 ppb). This result indicates that 
bacterial cells are either more sensitive to Cr(VI), or that mutagenicity is also occurring in the 
mammalian cells at concentrations like that in the bacteria, but that the mutations occurring 
are nonlethal or nonharmful. In either case, the information merits further research into Cr(VI) 
mutagenicity in a mammalian cell line. 
Additionally, this study focused on the cotreatment of antioxidants with Cr(VI). 
Specifically, both bacterial cells in the Ames test and human cells in the cell proliferation assay 
were exposed to both the toxicant and the protectant simultaneously. In both assays, the 
cotreated solution was prepared 1-10 hours before cell exposure. Because of this, the chemical 
interaction taking place between the two compounds likely occurs in solution. Another 
interesting continuation of this study would be examining the differences between a 
cotreatment with antioxidant (as performed here in this study) and a pre-treatment or post-
treatment with antioxidant. 
These data come to the scene at a point in time where millions of Americans are 
exposed to hexavalent chromium in their daily water supply (Andrews & Walker, 2016). The 
protective potential of antioxidants is promising, and applications of this research are 
numerous. For example, just as many European countries began adding fluoride to public water 
supplies in the early 90’s to prevent dental caries, antioxidant may be added to water supplies 
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known to have higher concentrations of Cr(VI), or areas at higher risk of Cr(VI) contamination. 
This reduction potential may also be applied to mitigate other powerful oxidizers. Though 
continued study is merited, this information further validates the protective potential of 
antioxidants and will be helpful for government agencies and organizations in determining safe 
levels of water chromium.  
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